Healios K.K. newly established the position of CSO (Chief Scientific Officer) as the chief executive officer of the research department to promote research on eNK cells and other programs in Japan and overseas. Healios changed its structure to achieve rapid R&D decision-making and rationalization of management in the field of regenerative medicine using somatic stem cells in light of the next development steps for ARDS (acute respiratory distress syndrome) and acute stroke becoming clear. Research and development in the field of iPSC regenerative medicines will be promoted under the leadership of the newly established CSO.

Formerly Executive Officers, Mr. Nishiyama and Mr. Kotera will continue to serve the company as outside advisors to support the development and manufacturing operations as well as promotion of the business, and Mr. Abe will serve as the General Manager of the Human Resources & General Affairs Department. Name: Masanori Sawada, Current position: Executive Vice President CMO (Chief Medical Officer) in charge of development & human resources and general affairs, Former position: Executive Vice President CMO (Chief Medical Officer). Name: Kouichi Tamura, Current position Executive Officer CSO (Chief Scientific Officer) in charge of research and manufacturing Head of Kobe Research Institute, Former position: Executive Officer in charge of research Head of Kobe Research Institute.